Given that the levels of both IL-10 and IL-1β decrease under IETD-fmk treatment, we hypothesize that, unlike most conventional treatments, caspase-8 inhibition is able to counteract both phases of SIRS; pro- and anti-inflammatory. Here, IL1B is linked to systemic inflammatory response syndrome.